Elan Corporation PLC
Elan Corporation, plc today announced that Japan's Patent Office has issued a
patent certificate for Elan's proprietary NanoCrystal(TM) Technology. Japanese
Patent Number 36020546, which expires January 24, 2012, protects intellectual
property related to Elan's NanoCrystal technology.
'This is a significant milestone in the development of new applications of our
NanoCrystal technology and may facilitate the expansion of our activities in
Japan, one of the world's most significant pharmaceutical markets. The patent
may allow us to work more closely with Japanese companies to help them develop
and commercialise compounds that exhibit poor water-solubility,' said Paul
Breen, Executive Vice President, Global Services & Operations, Elan.
Three pharmaceutical products have been commercialised in the U.S. incorporating
NanoCrystal Technology to date, with several additional product launches
anticipated over the next two years.
About Elan's NanoCrystal Technology
NanoCrystal technology may enhance the clinical performance of poorly
water-soluble drugs by transforming them into nanometer-sized particles. An
increasing number of the drug candidates synthesized each year by pharmaceutical
companies are poorly water-soluble. Many of these potentially innovative drug
candidates are often abandoned because of poor pharmacokinetic properties
including absorption, distribution, metabolism, and excretion. NanoCrystal
technology has the potential to rescue a significant percentage of these
chemical compounds. The drug in nano-form can be incorporated into common dosage
forms, including tablets, capsules, inhalation devices, sterile forms for
injection, with the potential for substantial improvements to clinical
performance. Elan's NanoCrystal Technology is protected by more than 130 U.S.
and foreign patents and patent applications. More information about Elan's
NanoCrystal technology is available at www.elan.com/drugdelivery.
Elan is a neuroscience-based biotechnology company that is focused on
discovering, developing, manufacturing, selling and marketing advanced therapies
in neurodegenerative diseases, autoimmune diseases and severe pain. Elan's
(NYSE:ELN) shares trade on the New York, London and Dublin Stock Exchanges.
NanoCrystal(TM) Technology is a registered trademark owned by Elan Pharma
International Limited Corporation, Ireland
CONTACT: Elan Corporation, plc
Emer Reynolds, 353-1-709-4000
Anita Kawatra, 212-407-5740